89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme
A Pilot Study of 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme
Sponsor: Memorial Sloan Kettering Cancer Center
Listed as NCT02410577, this NA trial focuses on Glioblastoma and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 10 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Jan 2021 — Dec 2022 [monthly]
Completed NA
▶ Show 5 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Completed NA
-
Oct 2018 — Apr 2019 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .